Clinical-stage biotech developing small-molecule drugs for vitiligo and immune-mediated skin diseases.
| Date | Round | Amount |
|---|---|---|
| Sep 2024 | Series A Biotech startup Ahammune Biosciences raised a $5M Series A led by pi Ventures to run phase-2 clinical trials of its vitiligo drug candidate. | $5M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.